Actinium Pharmaceuticals share price logo

Actinium Pharmaceuticals

AMEX: ATNM

$1.01

as on

Actinium Pharmaceuticals Stock Performance

as on August 28, 2026 at 6:59 am IST

  • Day's High

    $1.01
    $1.05

    3.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.74
    $1.80
    downward going graph

    27.22%

    Downside

    78.22%

    Upside

    downward going graph

Actinium Pharmaceuticals share price movements today

Previous Close
$1.01
Open
$1.01
Volume
685.2K
Market Cap
$33.9M
Day's Low - High
$1.01 - $1.05
52 Week Low - High
$0.74 - $1.80

Actinium Pharmaceuticals Historical Returns

1 Month Return
+ 18.21 %
3 Month Return
-14.41 %
1 Year Return
-42.61 %
3 Year Return
-83.22 %
5 Year Return
-83.33 %

Actinium Pharmaceuticals Stock Fundamentals & Key Indicators

Check Actinium Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$33.9M

EPS (TTM)

0.36

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

2.68

Industry PE ratio

-1.5979841897233202

PEG Ratio

0.009477485235924975

EBITDA

12.2M

Revenue (TTM)

35.1M

Profit Margin

101.13%

Return On Equity TTM

83.42%

Actinium Pharmaceuticals Stock Valuation

Track how Actinium Pharmaceuticals P/E has moved over time to understand its valuation trends.

Actinium Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-7.79x)

March 31, 2023

Industry (-1.60x)

December 31, 2025

Today (-1.25x)

December 31, 2025

Highest (-0.99x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -1.25x

Actinium Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Actinium Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$33.9M-83.33%2.68101.13%NA
BUY$45.3B655.66%NA0.00%NA
BUY$140.1B173.75%31.9286.04%NA
BUY$63.4B-60.84%-7.98-12.57%NA
BUY$85.3B22.84%19.984.86%0.44%

Stock Returns calculator for Actinium Pharmaceuticals Stock including INR - Dollar returns

The Actinium Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Actinium Pharmaceuticals investment value today

Current value as on today

₹62,538

Returns

-₹37,462

(-37.46%)

Returns from Actinium Pharmaceuticals Stock

-₹42,614 (-42.61%)

Dollar Impact

₹5,151 (+5.15%)

Analyst Recommendation on Actinium Pharmaceuticals Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Actinium Pharmaceuticals. Average target price of $3.5

Actinium Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Actinium Pharmaceuticals.

What analysts predicted

71.14%UPSIDE

Target Price

$3.5

Current Price

$1.01

Analyzed by

2 Analysts

Target

$3.50

Actinium Pharmaceuticals target price $3.5, a slight upside of 71.14% compared to current price of $1.01. According to 2 analysts rating.

Indian Investors' Interest in Actinium Pharmaceuticals Stock

Search interest for Actinium Pharmaceuticals Stock has increased by 57% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:57% versus previous 30 day period

Actinium Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
0
-
-
35
Gross Profit
0
0
0
0
-
-
0
0
0
35
Operating Income
-9
-12
-12
-7
-16
-7
-5
-6
-5
27
EBITDA
-8
-11
-11
-6
-15
-6
-4
-5
-5
28
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-8
-11
-11
-6
-15
-6
-5
-5
-5
27
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-8
-11
-11
-6
-15
-6
-5
-5
-5
27
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
0.00%
0.00%
100.00%

Actinium Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
1
1
0
-
0
Gross Profit
0
0
0
0
0
1
0
0
0
Operating Income
-26
-23
-22
-22
-24
-34
-51
-42
-36
EBITDA
-26
-23
-21
-21
-24
-32
-48
-37
-33
Interest Expense
0
0
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-26
-23
-21
-22
-24
-33
-48
-38
-33
Income Tax Expense
-
0
-
-
-
-
-
-
-
Net Income
-26
-23
-21
-22
-24
-33
-48
-38
-33
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
54.20%
100.00%
100.00%
0.00%
100.00%

Actinium Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-8
-11
-11
-6
-15
-6
-5
-5
-5
27
Operating Cash Flow
-7
-7
-11
-5
-7
-5
-6
-5
-5
-5
Investing Cash Flow
0
-
-
-
-
-
-
0
0
0
Financing Cash Flow
14
9
4
0
0
0
0
0
0
0
Change in Cash
7
1
-7
-5
-7
-5
-6
-5
-5
-5

Actinium Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-23
-21
-22
-24
-33
-48
-38
-33
Operating Cash Flow
-21
-20
-21
-21
-20
8
-47
-33
-24
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
18
16
17
76
35
23
14
29
0
Change in Cash
-3
-3
-4
54
14
31
-32
-3
-24

Mutual Funds that own Actinium Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Actinium Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.888979%
1222751
Fidelity Concord Street Trust
0.835276%
262623
TIAA-CREF Funds
0.273114%
85871
Nationwide Mutual Funds
0.1683%
52916
Bridgeway Funds, Inc.
0.12722%
40000

Global Institutional Holdings in Actinium Pharmaceuticals

Funds
Holdings
Vanguard
3.92%
iShares
0.34%
Bridgeway
0.13%

Insights on Actinium Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -5.94M → 27.90M (in $), with an average increase of 63.7% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 90.0K → 35.00M (in $), with an average increase of 99.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 496.3% return, outperforming this stock by 538.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 33.7% return, outperforming this stock by 116.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ATNM stock has moved down by -9.8%

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
OrganisationActinium Pharmaceuticals
Headquarters100 Park Avenue, New York, NY, United States, 10017
IndustryBiotechnology
CEOMr. Sandesh C. Seth M.B.A., M.S.
E-voting on sharesClick here to vote

Key Management of Actinium Pharmaceuticals

Name

Title

Dr. Madhuri Vusirikala M.D.

Vice President of Clinical Development BMT & Cellular Therapy

Mr. Sandesh C. Seth M.B.A., M.S.

CEO, Principal Financial Officer & Chairman

Dr. Paul Diamond Esq., Ph.D.

Vice President of Patent & Legal Counsel

Ms. Lynn M. Bodarky M.B.A.

Chief Business Officer

Dr. Steffen Heeger M.D., M.Sc., Ph.D.

Chief Medical Officer

FAQs

What is Actinium Pharmaceuticals share price today?

Actinium Pharmaceuticals share price today is $1.01 as on at the close of the market. Actinium Pharmaceuticals share today touched a day high of $1.05 and a low of $1.01.

What is the 52 week high and 52 week low for Actinium Pharmaceuticals share?

Actinium Pharmaceuticals share touched a 52 week high of $1.80 on and a 52 week low of $0.74 on . Actinium Pharmaceuticals stock price today i.e. is closed at $1.01,which is 43.89% down from its 52 week high and 37.40% up from its 52 week low.

What is Actinium Pharmaceuticals's market capitalisation today?

Actinium Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Actinium Pharmaceuticals Stock (ATNM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Actinium Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Actinium Pharmaceuticals Shares that will get you 1.4851 shares as per Actinium Pharmaceuticals share price of $1.01 per share as on August 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Actinium Pharmaceuticals Stock (ATNM) from India?

Indian investors can start investing in Actinium Pharmaceuticals (ATNM) shares with as little as ₹95.53 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.30 in Actinium Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Actinium Pharmaceuticals share’s latest price of $1.01 as on August 28, 2026 at 1:29 am IST, you will get 9.9010 shares of Actinium Pharmaceuticals. Learn more about fractional shares .

What are the returns that Actinium Pharmaceuticals has given to Indian investors in the last 5 years?

Actinium Pharmaceuticals stock has given -83.33% share price returns and 30.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?